Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Olive oil and prebiotics: a tasty way to fight muscle loss in seniors?

NCT ID NCT05485402

Symptom relief Sponsor: University Rovira i Virgili Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a diet rich in a special olive oil (high in phenolic compounds) plus prebiotic supplements could help people aged 60-80 who have sarcopenia (age-related muscle loss). The goal was to see if this approach could improve muscle mass, strength, and walking speed, and also reduce heart disease risk. 39 participants followed the diet for 12 weeks, with a 12-week follow-up to see if any benefits lasted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

39 people

The number who actually took part.

Started

Sep 2022

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women with and age equal to or greater than 60 years and until 80 years. * Written informed consent provided before the initial visit. * Sarcopenia assessment: low muscle strength based on grip dynamometry, kg (men \<30 kg; women \<20 kg) or low skeletal muscle mass index (SMI) based on bioimpedance analysis (BIA), kg/m2 (men \<8,87 kg/m2; women \<6,42 kg/m2) or low physical performance or physical function based on 4m gait speed, m/s (≤0,8 m/s) Exclusion Criteria: * Type 2 or insulin-dependent diabetes diagnosed. * Anemia (hemoglobin ≤13 g/dL in men and ≤12 g/dL in women). * Intestinal malabsorption diseases. * Fructose and/or sucrose intolerance. * Malnutrition (assessed by albumin \<3,5 g/dl). * Renal diseases. * Chronic alcoholism. * Current or past participation in a clinical trial or consumption of a research product in the 30 days prior to inclusion in the study. * Institutionalized elderly. * Failure to follow the study guidelines.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcopenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcopenia

Contacts and locations

Locations

  • Universitat Rovira i Virgili

    Reus, Tarragona, 43201, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.